Plain-English translation of NCT07323173 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called LBL-047, which is given as a single injection under the skin. Researchers want to understand whether this treatment is safe, how the body handles it, and whether it might help people with systemic lupus erythematosus—a disease where the immune system attacks the body's own tissues. The study will first test the medication in healthy volunteers at different dose levels, then move to people who have been diagnosed with mild to moderate lupus.
Lupus is a serious condition that can cause pain, inflammation, and organ damage, and there is a need for new treatment options. This trial is designed to see if this new medication could be a safe and effective addition to available lupus treatments.
You likely qualify if…
You likely don't qualify if…
Participants will receive a single injection under the skin of either the study medication or a placebo (inactive substance). The study is split into two parts: first, healthy volunteers will receive different dose levels to make sure the treatment is safe, and then people with lupus will receive the medication at a dose shown to be safe. Throughout the study, you will attend visits where the research team will check your health, take blood samples, and monitor how you feel over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China